Virax Biolabs and Fosun Diagnostics Forge a New Supply Agreement in Southeast Asia

Strategic Partnership Between Virax Biolabs and Fosun Diagnostics

On July 9, 2026, Virax Biolabs Group Limited (NASDAQ: VRAX) announced a landmark commercial supply agreement with Fosun Diagnostics. This arrangement, characterized as exclusive, opens the doors to six key Southeast Asian markets including Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. The agreement is aimed at enhancing access to Virax's ImmuneSelect product line, which is focused on immune profiling for research purposes.

Background of the Agreement

Virax Biolabs, through its UK-based subsidiary, is paving the way for a stronger foothold in the Southeast Asian market by collaborating with Fosun Diagnostics, a reputable name in the regional diagnostics field. This commercial supply agreement outlines a framework that enables immediate product supply based on purchase orders, thereby unlocking potential revenue streams in the short term while setting the stage for further commercial expansion in the future.

The ImmuneSelect product line, which comprises a range of tools such as ELISpot assay plates for measuring cellular immune responses, will be among the primary offerings to be supplied to Fosun Diagnostics. It's important to note that ImmuneSelect is categorized as research-use-only (RUO) and is distinct from the in-development diagnostic platform, ViraxImmune™, which is currently going through clinical and regulatory phases.

Enhancing Market Reach and Expansion

Virax views this agreement as a critical milestone that provides access to a broader customer base across Southeast Asia. With Fosun Diagnostics’ established commercial infrastructure and network, Virax can efficiently distribute its immune profiling products while exploring opportunities for additional product lines and increased volume supply arrangements. The structure of this collaboration also allows for potential OEM or private-label opportunities, thereby expanding the product offerings further.

Immediate Commercial Opportunities

Fosun Diagnostics has identified an immediate market demand, particularly linked to tuberculosis-related research applications in Thailand, and is ready to initiate preliminary evaluations through its extensive regional network. With pricing strategies that incorporate volume-based tiers, Virax aims to create scalable commercial opportunities across the ASEAN region.

James Foster, Chairman and CEO of Virax Biolabs, expressed his elation regarding the partnership, highlighting its potential to catalyze the commercial rollout of ImmuneSelect across Southeast Asia.

Statements from Leadership

Leon Zhang, International Commercial Head for China Domestic Business at Fosun MedTech, shared similar enthusiasm for the partnership, recognizing the strength of Virax's ELISpot platform as a vital part of their evaluation initiatives across multiple regional markets. This teamwork signifies not only a commercial agreement but also a collaborative effort to push forward innovation in diagnostic technologies.

About the Companies

Virax Biolabs Group Limited stands at the forefront of biotechnology, concentrating on immune response detection and T cell immune profiling. With initiatives like ViraxImmune™ focusing on chronic immune dysfunction and post-acute infection syndromes, Virax is committed to exploring cutting-edge technologies in the healthcare landscape.

Fosun Diagnostics, a leading entity in in vitro diagnostics, empowers healthcare through innovative diagnostic solutions and is part of Fosun Medtech, a significant division of Fosun Pharma, an internationally recognized pharmaceutical and healthcare group.

Conclusion

The collaboration between Virax Biolabs and Fosun Diagnostics marks a promising acquisition of strategic significance, laying a solid foundation for enhanced market presence within Southeast Asia. This partnership not only aims at immediate revenue opportunities but also emphasizes long-term growth potential through expanded product offerings and collaborative research efforts.